Pirofsky B
Am J Med. 1984 Mar 30;76(3A):53-60. doi: 10.1016/0002-9343(84)90320-6.
An immune globulin preparation specifically modified for intravenous administration has been employed therapeutically in 30 patients with primary immunodeficiency disease. Our results of this long-term study are summarized within three major categories: (1) Levels of serum IgG produced and maintained after intravenously administered serum immune globulin infusions of 100 to 500 mg/kilo. The disappearance pattern of infused IgG is outlined and individual patient variations emphasized. (2) The therapeutic effects of intravenously administered serum immune globulin therapy are reported and related to dosages of intravenously administered serum immune globulin administered and serum levels of IgG maintained. (3) The incidence and nature of detrimental side effects are outlined, and methods to reduce this problem are indicated. It is recommended that patients with primary immunodeficiency be given from 150 to 200 mg/kilo intravenously administered serum immune globulin, every four weeks, as prophylactic therapy to reduce acute infectious complications. A method to establish an optimum therapy for a specific patient is presented.
一种专门为静脉注射而改良的免疫球蛋白制剂已用于30例原发性免疫缺陷病患者的治疗。我们这项长期研究的结果总结为三大类：（1）静脉注射100至500毫克/千克血清免疫球蛋白后产生并维持的血清IgG水平。概述了注入IgG的消失模式，并强调了个体患者的差异。（2）报告了静脉注射血清免疫球蛋白治疗的疗效，并将其与静脉注射血清免疫球蛋白的剂量以及维持的血清IgG水平相关联。（3）概述了有害副作用的发生率和性质，并指出了减少该问题的方法。建议原发性免疫缺陷患者每四周静脉注射150至200毫克/千克血清免疫球蛋白，作为预防治疗以减少急性感染并发症。提出了一种为特定患者建立最佳治疗方案的方法。
